Esperion Therapeutics Inc (ESPR.OQ)
20 Jul 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2012||President, Chief Executive Officer, Director|
|36||2018||Chief Financial Officer and Principal Financial Officer|
|64||2014||Chief Operating Officer, Executive Vice President - Research & Development|
|60||2015||Independent Lead Director|
- BRIEF-Esperion Announces Third Pivotal Phase 3 Study Of Bempedoic Acid Meets Primary Endpoint
- Esperion's cholesterol drug safe, effective in new late-stage study
- BRIEF-Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint
- BRIEF-Esperion Posts Qtrly Loss Per Share $1.73
- UPDATE 1-Esperion's drug clears study as add-on cholesterol treatment